The problem: a peptide you cannot normally swallow

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a medicine that mimics the natural GLP-1 hormone, acting on appetite-regulating areas of the brain to increase satiety, reduce hunger and cut food cravings.[2] The catch is chemistry. Semaglutide is a peptide: a large, delicate molecule that stomach acid and digestive enzymes would ordinarily break down before it reached the bloodstream. That is why the original Wegovy is a once-weekly injection, and why potent GLP-1 medicines were injectables rather than pills for years.[1] Making semaglutide work as a tablet meant solving that absorption problem — the answer was a co-formulated absorption enhancer called SNAC.

What SNAC is, and where it came from

SNAC is short for sodium N-[8-(2-hydroxybenzoyl)amino]caprylate — also known as salcaprozate sodium, and branded Eligen® SNAC. It is co-formulated with semaglutide in the tablet. According to published descriptions of the technology, SNAC creates a localised protected zone at the interface between the dissolving tablet and the stomach lining, raising the local gastric pH to roughly 5 so that pepsin (a digestive enzyme) is inactivated and semaglutide can cross the stomach lining intact.[7]

Because absorption depends on that narrow SNAC "window", the tablet is taken under strict rules — swallowed whole on an empty stomach with only a little plain water, then a wait before eating, drinking or taking anything else, or too little of the drug is absorbed. Those rules are covered on our Wegovy pill dosage page.[7]

The Emisphere acquisition

The Eligen SNAC platform did not originate inside Novo Nordisk. It came from a company called Emisphere Technologies, with whom Novo Nordisk had collaborated on the technology since 2007.[6] To secure full ownership of the platform underpinning its oral-semaglutide franchise, Novo Nordisk moved to buy Emisphere outright. The acquisition was reported as announced on 6 November 2020 and completed on 8 December 2020, giving Novo Nordisk full access to the SNAC platform.[6]

Key takeaway

The Wegovy pill exists because two things work together: the active molecule (semaglutide, the same one in the injection) and an absorption technology (Eligen SNAC) that lets a fragile peptide survive the stomach. Novo Nordisk secured that technology by acquiring Emisphere outright in 2020.[6]

From Rybelsus to the Wegovy pill: PIONEER came first

SNAC-based oral semaglutide was not new in 2025. It was first commercialised as Rybelsus, an oral semaglutide tablet licensed for type 2 diabetes at 3 mg, 7 mg and 14 mg once daily.[5] The evidence for that use came from Novo Nordisk's PIONEER programme in type 2 diabetes — including PIONEER PLUS, which tested higher research strengths of 25 mg and 50 mg against the established 14 mg dose.[8]

The Wegovy pill is best understood as the higher-dose, weight-management application of that same oral-semaglutide technology: same active molecule, same SNAC delivery, but a distinct product with a 25 mg maintenance dose and a different purpose.[1][5] One thing worth keeping straight is the numbering: Rybelsus uses a 3/7/14 mg ladder,[5] the Wegovy pill titrates to 25 mg,[1] and the obesity trials used research strengths of 25 mg and 50 mg[8] — three separate systems that should not be conflated.

The OASIS programme: testing the pill for weight loss

The evidence that oral semaglutide could produce meaningful weight loss came from the phase 3 OASIS programme, which tested once-daily oral semaglutide at 25 mg and 50 mg in obesity. Novo Nordisk has reported the programme as spanning four trials in around 1,300 adults with obesity, or overweight plus one or more weight-related conditions.[8]

OASIS 1 — the earlier 50 mg read-out

OASIS 1 was a 68-week, double-blind, randomised, placebo-controlled trial in adults with overweight or obesity without type 2 diabetes. It tested the 50 mg dose and reported a mean weight change of −15.1% with oral semaglutide versus −2.4% on placebo at week 68. The results were published in The Lancet in 2023.[3] One caveat: 50 mg is not the approved dose. The licensed Wegovy pill is 25 mg, so the on-label efficacy story rests on the later OASIS 4 trial.

OASIS 4 — the trial behind the approved 25 mg pill

OASIS 4 was the approval-supporting trial for the 25 mg strength: a 64-week (71 weeks including a 12-week escalation and 7-week follow-up) phase 3b study of oral semaglutide 25 mg (n=205) against placebo (n=102) — 307 adults with obesity or overweight but without diabetes, alongside lifestyle support. The population was around 79% women, with a mean age of 48.[4]

Its two headline weight-loss figures answer slightly different questions, so each carries a statistical "estimand":

  • If fully adhered (the trial-product estimand): mean weight change of −16.6% versus −2.7% on placebo.[1]
  • Regardless of adherence (the treatment-policy estimand): mean weight change of −13.6% versus −2.4% on placebo.[9]

Around 76% of people on the drug lost at least 5% of body weight, against 31% on placebo.[9] For the larger threshold of at least 20% weight loss, Novo Nordisk describes "one in three" people (the adherent figure), while the treatment-policy figure was 30% versus 3% — the same trial viewed through two estimands, not a disagreement.[1][4] BMI, waist circumference, HbA1c, lipids and C-reactive protein also improved versus placebo. OASIS 4 was published in the New England Journal of Medicine on 17 September 2025.[4]

Regulatory milestones

In the United States, the FDA approved the tablet on 22 December 2025 for adults with obesity, or overweight with weight-related medical problems, to lose weight and keep it off alongside a reduced-calorie diet and more physical activity; the US label also carries a cardiovascular indication — reducing the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.[1][9]

In the United Kingdom, the MHRA approved the tablet on 11 June 2026, described as the first oral GLP-1 licensed for weight management in the UK.[2] (Two secondary UK summaries give 12 June 2026, but the stronger sources point to 11 June, and as of mid-2026 no confirmed EU/EMA approval had been found.)[10] In UK use the tablet is titrated slowly — a 1.5 mg → 4 mg → 9 mg → 25 mg ladder with a minimum of one month at each step — to limit gastrointestinal side effects during escalation; the full schedule is on our dosage page.[2]

The manufacturing story is really the SNAC story

For the Wegovy pill, the defining manufacturing move was securing the absorption technology rather than building any single plant — which is why the 2020 Emisphere acquisition mattered so much, removing Novo Nordisk's dependence on an outside licensor for the SNAC platform.[6] Detailed production-capacity figures for the 25 mg pill were not established in the sources reviewed for this page, so we do not quote any here.

A note on safety and access

The US labelling carries a boxed warning about a risk of thyroid C-cell tumours, including medullary thyroid carcinoma, based on rodent data — a warning that runs across the semaglutide class.[9] The most commonly reported side effects are gastrointestinal — nausea, diarrhoea, vomiting, constipation and abdominal pain among them — generally mild to moderate and worst during dose escalation, with an overall profile reported as comparable to the injection.[9][4] We set out the warnings, contraindications and precautions on our side effects page. If you experience a side effect from any medicine, report it through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk, and speak to your GP or pharmacist.

On access, the point is simple: this is a prescription-only medicine. Lawful UK supply happens only through GPhC-registered pharmacies against a valid prescription, after a consultation in which a prescriber decides whether it is a suitable option — one option a prescriber may discuss, never something anyone must take.

Frequently asked questions

Who makes the Wegovy pill?

Novo Nordisk. The absorption technology it relies on, the Eligen SNAC enhancer, came from Emisphere Technologies — a company Novo Nordisk had collaborated with since 2007 and acquired outright in 2020.[6]

What is SNAC and how does it let semaglutide work as a pill?

SNAC (salcaprozate sodium) is an absorption enhancer co-formulated with semaglutide, a peptide that stomach acid and enzymes would normally destroy. According to published descriptions of the technology, SNAC creates a small protected zone at the tablet-mucosa interface, raising local stomach pH so the peptide can be absorbed intact. Because absorption depends on that narrow window, the tablet has strict dosing rules.[7]

Is the Wegovy pill the same as Rybelsus?

No. Both are SNAC-based oral semaglutide tablets, but they are different products. Rybelsus is licensed for type 2 diabetes at 3 mg, 7 mg or 14 mg once daily; the Wegovy pill is a higher-dose oral semaglutide, with a 25 mg maintenance dose, developed for weight management.[5]

When was the Wegovy pill approved?

The US FDA approved the tablet on 22 December 2025.[1] The UK MHRA approved it on 11 June 2026, making it the first oral GLP-1 licensed for weight management in the UK. It is a prescription-only medicine.[2]

References

  1. Novo Nordisk. FDA approval of the Wegovy pill (oral semaglutide 25 mg) — company announcement. novonordisk.com
  2. The Pharmaceutical Journal. "MHRA approves semaglutide oral tablets for weight loss" (UK approval date, first oral GLP-1 for weight management, titration ladder, administration rules). Cited from the compiler's verified research notes.
  3. The Lancet. OASIS 1 — oral semaglutide 50 mg in adults with overweight or obesity without type 2 diabetes, 2023. thelancet.com
  4. American College of Cardiology. OASIS 4 journal scan (oral semaglutide 25 mg; NEJM, 17 September 2025). Cited from the compiler's verified research notes.
  5. US Food and Drug Administration. Rybelsus (oral semaglutide) Prescribing Information — 3/7/14 mg strengths and SNAC administration, for comparison. accessdata.fda.gov
  6. DCAT. "Novo Nordisk completes acquisition of Emisphere Technologies" (Eligen SNAC platform; 2007 collaboration; 6 November and 8 December 2020 acquisition dates). Cited from the compiler's verified research notes.
  7. Biopharma PEG. "What is SNAC in oral semaglutide?" (SNAC chemistry and absorption mechanism). Cited from the compiler's verified research notes.
  8. Novo Nordisk / ObesityWeek 2025. Oral semaglutide 25 mg data and obesity pipeline overview (OASIS, PIONEER and SOUL programmes). Cited from the compiler's verified research notes.
  9. PR Newswire (Novo Nordisk). "FDA approves Novo Nordisk's Wegovy pill…" (US indications, boxed warning, ≥5% weight-loss figures, treatment-policy estimand, side-effect list). Cited from the compiler's verified research notes.
  10. Secondary UK summaries of the MHRA approval — the alternative 12 June 2026 date, and the observation that no EU/EMA approval had been confirmed as of mid-2026. Cited from the compiler's verified research notes; not hyperlinked as a matter of house policy.

As a matter of house policy this site links directly only to regulator, manufacturer and peer-reviewed journal pages. Facts drawn from other sources named above (industry and specialist-press reports gathered in our research notes) are attributed to those sources but not hyperlinked, and we never link to any pharmacy, clinic or retailer.